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Kinetic on and off rate constants for many receptor ligands are difﬁcult to determine with regular
radioligand binding technique since only few of the ligands are available in labeled form.
Here we developed a new and simple radioligand binding method for determining the kinetic off-rate
constant for unlabeled ligands, using whole cells expressing α2A- and α2C-adrenoceptors. The new
method involves pre-incubation with unlabeled ligand, centrifugation of microtiter plates in order to
adhere the cells to the bottom surface, and then upside-down centrifugation of the plates for few sec-
onds to wash away the non-bound fraction of the pre-incubated ligand. The ﬁnal on-reaction assay for
the radioligand is then started by quick addition of a relatively fast-associating radioligand to the cells.
The curve obtained is deﬁned by a fairly simple mathematical formula that reﬂects the simultaneous
dissociation of pre-incubated ligand and association of the radioligand. The method proved to produce
highly reproducible results in determining the koff constants for various unlabeled ligands.
The results show that the α2C-selectivity of MK912 depends mainly on a very slow off-rate at the α2C-
adrenoceptor subtype. Regarding the markedly α2C- over α2A-selective compound spiroxatrine, its much
faster on-rate at α2C- than α2A-adrenoceptors explains much of its exceptional α2C-selectivity.
Several new techniques for determining the kinetic component of ligand-receptor interactions at
molecular level are currently developing. As a reference, based on standard radioligand binding tech-
niques, the present study describes a simple and robust experimental and mathematical procedure for
determining koff constants of unlabeled drugs.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In a recent review, the importance of quantitative data re-
garding drug interaction with receptors was highlighted (Bylund
and Toews, 2014). It was pointed out that such interaction almost
always follows well-deﬁned mathematical relationships that are
based on receptor theory. In the same special issue, the im-
portance of drug-receptor theory in the ﬁeld of pharmacology in
biomedical research was highlighted (Kenakin and Williams,
2014). To date, almost all studies involved in determining the af-
ﬁnity of many ligands to a receptor have been performed at
equilibrium. Thereby, the kinetic component of the ligand-re-
ceptor interaction becomes undervalued (Pollard, 2010; Hoffmann
et al., 2015). The shortage of kinetic studies for unlabeled ligands isr B.V. This is an open access article
Biomedical Center, Box 593,
én).probably due to the difﬁculty of performing and analyzing such
kinetic experiments, in which, when including a radioligand, four
kinetic constants plus the time factor are participating simulta-
neously in the process. In the present study, we present an ex-
perimental method that reduces the complexity of the experi-
mental data and consequently eases the mathematical analysis.
The new radioligand binding experimental method was used to
determine the kinetic off-rate constants for several unlabeled
drugs at α2A- and α2C-adrenoceptors.
Previously, other studies have described different experimental
and mathematical strategies for determining the kinetic constants
for unlabeled small ligands acting at G protein-coupled receptors.
For example, Motulsky and Mahan (1984) described the mathe-
matics for analyzing the curves obtained after the simultaneous
addition of radioligand and competitor, including four rate con-
stants in the analysis. Another study presents a laboratory manual
account for the full experimental procedure (Sykes et al., 2010). Yet
another study addressed the same subject as the present study, i.e.
the development of a simpliﬁed method for the determination ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Both that study and the present study use an approach consisting
of pre-incubating the receptor preparation with ligand, washing
out free ligand molecules, adding radioligand and monitoring its
binding after various times. However, the practical solutions and
technical details differ widely (see Section 4). The methodology
presented in the present study is rather robust, well suited for
studies aiming at determining the off-rate constant for many un-
labeled ligands at a receptor.
In a recent study, the Kd value of the radioligand [3H]-
RX821002, and the Ki values of seven competing drugs at the
human α2A-, α2C-, and 4 chimeric α2A-/α2C-adrenoceptors were
determined (Jahnsen and Uhlén, 2013). The results gave clues
about what regions of the receptors are causing the subtype-se-
lectivity for the ligands. In the present study, aiming at gathering
more information about speciﬁc ligand-receptor interactions, the
off-rate constants for [3H]-RX821002 and 8 unlabeled drugs were
determined at the human α2A- and α2C-adrenoceptors and at two
chimeric α2A-/α2C-adrenoceptors. The mathematical differential
equation formula used for ﬁtting the data to the curves, described
by Malany and coworkers (2009), is evaluated in some detail.2. Materials and methods
2.1. Materials
[3H]-RX821002 (NET1153; 49Ci mmol1; [3H]2-(2-methoxy-
1,4-benzodioxan-2-yl)2-imidazoline hydrochloride) was from
PerkinElmer. Atipamezole (A-9611), chlorpromazine hydrochloride
(C-8138), MK912 (M-7065), yohimbine (Y-3125), Dulbecco's
modiﬁed Eagle's medium (DMEM) (d-6429), fetal calf serum (F-
7524), penicillin-streptomycin (P-4333) and trypsin/EDTA (T-
3924) were from Sigma-Aldrich (St. Louis, MO, U.S.A.). BRL44408
(1133), RS79948–197 (0987) and RX821002 (1324) were from To-
cris, Bristol, UK. Spiroxatrine (S-103) was from RBI, Natick, MA, U.S.
A. PCR primers were purchased from TAG Copenhagen A/S, Den-
mark. Lipofectamine™ 2000, OptiMEM, and Platinum Pfx DNA
polymerase were from Invitrogen. The wild type α2A-adrenoceptor
(RefSeq NM_000681), and wild type α2C-adrenoceptor (RefSeq
NM_000683) were inserted in the expression vector pcDNA3.1þ .
The chimeric constructs AppC and CppA have been described
previously (Jahnsen and Uhlén, 2013). The HEK293 (Human Em-
bryonic Kidney) cell line was from ATCC (Rockville, U.S.A.). All
other chemicals were purchased from the appropriate commercial
sources.
2.2. Chemical compounds studied in this article
Atipamezole hydrochloride (PubChem CID: 13649426);
BRL44408 (PubChem CID: 121850); Chlorpromazine hydrochloride
(PubChem CID: 6240); MK912 (PubChem CID: 5311298); RS79948–
197 (PubChem CID:9908991); RX821002 (PubChem CID: 108094);
Spiroxatrine (PubChem CID: 5268); Yohimbine hydrochloride
(PubChem CID: 6169).
2.3. Selection of ligands
The radioligand [3H]-RX821002 is a small, fairly hydrophilic
drug, showing fast on-rate at the α2A- and α2C-adrenoceptors, and
low non-speciﬁc binding to the HEK293 cells. [3H]-RX821002 is
therefore an excellent radioligand for the study. Spiroxatrine and
chlorpromazine were chosen to be tested because these molecules
are bulky and α2C/α2B- over α2A-selective (Laurila et al., 2011),
MK912 because it is bulky and α2C- but not α2B- over α2A-selective
(Uhlén et al., 1998), BRL44408 because it is α2A-selective, andatipamezole and RX820102 because they are small and non-se-
lective molecules (Jahnsen and Uhlén, 2013), RS79948–197 and
yohimbine were included since they are non-selective (Uhlén
et al., 1998), but structurally remind of MK912.
2.4. Plastic ware
The drug MK912 sticks to polystyrene (PS) surfaces, but not to
polypropylene (PP) (Uhlén et al., 1994). Therefore, MK912 was
dissolved, diluted, and assayed in PP tubes and PP microtiter
plates. In other cases, PS microplates were used, since PS plates are
transparent, enabling casual observation of the cells in a micro-
scope. For upside down centrifugation, Greiner 96-well ﬂat bottom
microtiter plates (polystyrene # 655101; polypropylene # 655201)
were ﬁt upside down into slightly trimmed bottom parts of Finntip
ﬁlter 200 μl yellow tip boxes (# 94052300) from Thermo Fisher
Scientiﬁc Oy, Vantaa, Finland, and then centrifuged.
2.5. Cell culture
The HEK293 cells were grown in standard tissue culture plastic
material at 37 °C, 95% air, 5% CO2, in Dulbecco's modiﬁed Eagle's
medium (DMEM), supplemented with 9% fetal calf serum and
100 U/ml penicillin and 0.1 mg/ml streptomycin. Cells were sub-
cultured every 3–4 days, by detachment with 0.5 mg/ml trypsin
and 0.2 mg/ml EDTA.
2.6. Transient expression
The HEK293 cells were transiently transfected with the re-
ceptor constructs. 1.2 μg of plasmid DNA was diluted in 245 μl of
OptiMEM, and 6 μl of Lipofectamine was diluted in 245 μl of Op-
tiMEM. 5 min later these two solutions were mixed. After 30 min
of incubation, the complex was added to HEK293 cells in 25 cm2
culture dishes in a total volume of 2.8 ml of OptiMEM. After
transfection, the cells were further cultured for 48 h.
2.7. Cell preparation
Cells transfected with receptor constructs were detached from
25 cm2 culture dishes with 8 ml of isotonic 50 mM Tris, 1.5 mM
EDTA, 100 mM NaCl, pH 7.5. Each cell suspension was centrifuged
at 400 g for 3 min, and the cell pellets were re-suspended in 4 ml
of binding buffer (50 mM Tris, 100 mM NaCl, pH 7.5). Cell clumps
were thoroughly dispersed by pipetting up and down many times
with a 1-ml pipette. The suspensions were further diluted (12
times for α2A, 6 times for CppA, and 3 times for α2C and AppC) in
order to obtain about 0.1 nM receptor concentration in the pre-
incubation assays.
2.8. [3H]-RX821002 binding to whole cells, for obtaining the koff and
kon constants for the radioligand
For the radioligand bound to a receptor, the koff value is easily
measured in radioligand binding experiments by blocking the on-
reaction with a high concentration of an antagonist (LR¼LReq*exp-
k°ff*t). In order to determine the koff constant for [3H]-RX821002 at
the 4 tested receptors, 125 μl of cell suspension aliquots were
mixed with 25 μl radioligand in the binding assays. After 60 min of
incubation, one microplate row, with assays representing the
binding equilibrium at T0, was ﬁltered. To the remaining assays,
150 μl of 20; μM atipamezole was added, and then, after various
times the assays were ﬁltered.
The on-rate constant (kon) is somewhat more complicated to
measure, since the experimental on-reaction curve also involves
the koff value, the formula being LR¼LReq*(1-exp-(kon*Lþkoff)*t).
Table 1.
The kon and koff rate constants for [3H]-RX821002, determined at native α2A- and α2C-adrenoceptors and at two chimeric receptors. Shown are the rate constant values 7
StdP, and number of experiments. The experiments were performed on transfected whole cells at room temp.
α2A α2C AppC CppA
kon, association rate constant (nM1min1) 0.05570.026 (19) 0.18970.127 (19) 0.30970.189 (15) 0.04270.028 (15)
koff, dissociation rate constant (min1) 0.11370.016 (5) 0.23870.066 (4) 0.11670.018 (4) 0.20670.041 (4)
Fig. 1. A-F. On- and off-reaction curves for [3H-RX821002] at α2A, α2C, AppC, and CppA receptors. Panel A shows on-reaction curves for [3H-RX821002]. The concentration of
the radioligand was 2.36 nM. Panel B shows the off-kinetic curves for 1.73 nM [3H]-RX821002, obtained after diluting the assay 2-fold and at the same time blocking re-
binding with 10 μM atipamezole. Panels C-F show the on-reaction curves for [3H-RX821002] at α2A, α2C, AppC, and CppA receptors, after pre-incubation with 19Ki of the
unlabeled competitors. The on-reaction curves enable analysis of the off-rate of the pre-incubated competitors, by validating the delay inﬂicted on the [3H]-RX821002 on-
reaction curves by the competitors. The concentration of [3H]-RX821002 in the shown examples were 2.0 nM, i.e. 4.5Ki for α2A, 4.1Ki for α2C, 8.3Ki for AppC, and
2.3Ki for CppA.
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establish the kon value from an on-reaction curve. In principle
125 μl of cell suspension were mixed with 25 μl radioligand in the
binding assays, and after various times the assays were ﬁltered.
The ﬁltering was performed on Whatman GF/C ﬁlters, using a
Brandel cell harvester. Radioactivity retained on the ﬁlters was
counted in a Beckman β-scintillation counter. Curves were ﬁtted
using GraphPad Prism. The koff and kon constants obtained from
these experiments are presented in Table 1, and the curves are
shown in Fig. 1A-B.2.9. Experimental design developed for the determination of koffconstants for unlabeled drugs
In order to facilitate the mathematical analysis, we developed
an experimental design where the impact of the on-reaction for
the competitors was almost eliminated, and therefore the on-rate
could be approximated to zero. Using whole cells in suspension,
the cell surface receptors were pre-incubated for 1 h in 96-wells
microtiter plates (see paragraph 2.3) with a high (19xKi) con-
centration of an antagonist in order to obtain 95% saturation of
antagonist binding to the receptors. The assay volume was 150 μl.
Then, the microtiter plates were centrifuged at 3000 rpm (1110 g)
for 3 min. This attached the HEK 293 cells with antagonist-blocked
receptors to the bottom surface. The microplate was then cen-
trifuged upside-down at 600 rpm (44 g) for 10 s to remove the
S. Uhlén et al. / European Journal of Pharmacology 788 (2016) 113–121116liquid and unbound ligand while retaining cells, including bound
ligand, attached to the bottom surface. Immediately, 300 μl of
binding buffer (including about 2 nM [3H]-RX821002) was added
rather forcefully to the cells. Thereby, most of the HEK293 cells
became re-suspended, due to that cell attachment was weak since
attachment of the cells had been achieved just by the previous
centrifugation in the calcium free buffer. This step also deﬁnes T0
in the on-reaction for the radioligand as well as T0 in the off-re-
action for the antagonist. Thereafter, the assays were ﬁltered at
different time points. The ﬁrst ﬁltration was performed after 30 s,
then after 2, 6, 15, 36 and 72 min. At T0 the on-rate for the binding
of [3H]-RX821002 to receptors will be very small, since there are
very few free receptors available. Depending on the off-reaction
for the antagonist more receptors become available for [3H]-
RX821002 to bind to. The off-reaction of the unlabeled ligand is
easily inferred from the delay imposed on the on-reaction curve of
the radioligand.
In practice, from each one-day experiment we obtained the koff
constants of 4 ligands at 2 different receptors, with n¼1. This
equals the koff constants of 8 ligands at 4 different receptors after
12 one-day experiments, with n¼3. Some advice on the applica-
tion of the experimental method is provided in supplement 1.
2.10. Formulas used for the curve ﬁtting
The differential equation developed by Malany et al. (2009)
describes the on-reaction curve for the radioligand when the re-
ceptors have been pre-incubated with a competitor as described
above. In their analysis it is assumed that all receptors are blocked
by the pre-incubated competing drug at the time of addition of the
radioligand, and that the free concentration of competitor, left
from the pre-incubation or derived from subsequently dissociated
bound competitor, is negligible. Under these conditions, the
binding curve is deﬁned by Eq. (1):
= *( * ) ( * + )
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The ﬁrst part of the equation above, i.e. RL¼Bmax*(k1*L)/
(k1*Lþk2)*(1exp-(k1*Lþk2)*t), describes the association binding
curve for the radioligand in the absence of a competitor. Within
this part, the term k1*L/(k1*Lþk2) describes occupancy based on
the rate constants, while (1exp-(k1*Lþk2)*t) describes the asso-
ciation rate.
The second part of the equation, i.e. ((k1*L)/(k1*Lþk2-k4))*
(Bmax*(exp(k1*Lþk2)*t-exp-k4*t)), describes the factor to be sub-
tracted from the ﬁrst part due to the pre-bound competitor. This
factor always has a negative value, lowering the on-rate of the
radioligand, especially at early time points of the reaction. It is this
part that makes Eq. (1) a differential equation (see Supplements
3A-B for details).
The formula actually used in the present study (Eq. (2), below)
is a slight modiﬁcation of Eq. (1), and describes the on-reaction
curve for the radioligand when initially only 95% of the receptors
are blocked. This level of blockade occurs after pre-incubationwith
the competing drug at a concentration 19 times its Ki value. The
explicit writing of Eq. (2) in the curve ﬁtting software Graph Pad
Prism is detailed in Supplement 2.
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k4The curve ﬁtting becomes fairly easy. The on-rate constant of
the radioligand k1 is detectable in the control curve, and is then set
constant for all curves in that particular experiment (exempliﬁed
in Fig. 1(C)-F). The off-rate constant of the radioligand k2 was
obtained in earlier experiments, and is also set constant. The
concentration of the radioligand L can be approximated to [L]E
[L]added, or can be calculated precisely as [L]¼[L]added-[LR]. Since
very little competitor is present in the ﬁnal radioligand binding
assay almost no receptors are blocked by competitor at the ﬁnal
equilibrium, and LReq can be approximated as being shared among
the control curve and all the other curves in that experiment. It
can be noted that the competitor’s kon constant, k3, is absent from
the formula, since the on-reaction of the competitor is negligible
due to the low concentration of the competitor after the washout
of free competitor, and due to the blocking effect by the radi-
oligand and the large 300 μl ﬁnal assay volume. The remaining
rate constant, i.e. the searched for koff constant for the competing
drugs, k4, should be well detectable using our experimental set-up.
The best applicability is for drugs where the t1/2 of the drug is
longer than the duration of time before the ﬁrst measurement,
which in our case was 30 s
Each experiment aimed at determining the koff constant of
unlabeled drugs included six curves, whereof one duplicate con-
trol curve for determining the on-rate constant of the radioligand
in that particular experiment. After calculating k1 from the control
curves, k1 and k2 were set constant in the full 6-curve analysis (2
control curves and 4 curves obtained after preincubation with
antagonists), and the Bmax value was set shared for the 6 curves.
Except the shared Bmax value, the only constant the mathematical
analysis had to deﬁne was the koff constant of the pre-incubated
unlabeled drugs, i.e. the k4 constants. Eq. (2) describes the curves
obtained by the herein described experimental design, and under
these conditions Eq. (2) is fully sufﬁcient, and easier to use than
the full 4 kinetic constant analysis described by Motulsky and
Mahan (1984). The main limitation of our method is that only
drugs with half-lives in the range 160 min were readily ana-
lyzable, i.e. drugs with koff constants between 0.693 min1 and
0.012 min1 (t1/2¼ ln2/k4). At the fast dissociation rate extreme,
the dissociation rate was hard to detect for competitors having k4
values higher than 1.386 min1, i.e. when it takes less than half a
min for the pre-incubated drug to dissociate from half of the
receptors.
Pre-incubating with not more than 19 fold the Ki values of the
unlabeled compounds seems to avoid the problem of residual
presence of competitors in the ﬁnal assays (such “contamination”
was seen with higher doses in pilot experiments). Using ligand
pre-incubation concentrations at 19X their Ki values, all curves in
the experiments approached the shared Beq after 72 min, except
the curves with MK912. However, even for MK912 the analysis
indicated that the residual blocking of [3H]-RX821002 binding by
pre-incubated MK912, at the α2C- and AppC-adrenoceptors, at
72 min, was due to not yet dissociated molecules, since the drug
was continuously dissociating for up to 3 h in experiments with
extended incubation times (not shown). In addition, pilot experi-
ments performed at 37 °C showed that all MK912 eventually dis-
sociated from pre-incubated α2C-adrenoceptors,
In a study resembling the present study, Packeu et al. (2010)
used plated cultured cells in their approach to determine the off-
rate constant of unlabeled ligands. They introduced the term “two-
step” procedure, involving a pre-incubation step with unlabeled
ligand. The main technical differences between their study and our
study are that we started with cell suspensions instead of plated
cells, and we removed free ligand by upside-down centrifugation
instead of aspiration. Using cell suspensions is very convenient,
especially when many drugs are to be tested, since the cell solu-
tions are homogeneous and can be diluted at will, and there is no
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periment. Un-binding of the pre-incubated ligand, as well as
binding of the radioligand, occur at cells which to a large extent
had become re-suspended by the forceful addition of the diluting
radioligand solution. This allows good diffusion accessibility for
the ligands. In addition, our mathematics is even more reductive
than that of Packeu and coworkers, since we use just one con-
centration of pre-incubated competitor, while they constructed
dose-response curves. Our on-reaction curves represent the same
type of curves that are present in their Figure 4C.3. Results
3.1. Experimental methodology
The concept behind the present study was to practically elim-
inate the on-reaction of the competitors at the stage after the pre-
incubation. Thereby, we arrive at a simpler mathematical formula.
At the start of the present project, such an elimination of the on-
reaction seemed straightforward in theory, but technically it
turned out to be more difﬁcult than anticipated. In series of pilot
experiments we tried in vain an experimental setup where
membrane preparations expressing the α2A-adrenoceptors were
pre-incubated with competitors. After the pre-incubation, excess
competitor was washed away by centrifugation at high speed
(38,000 g), and the supernatant discarded. However, re-suspen-
sion of the pellets took too long time, and no reproducible results
were obtained. Therefore, we turned to whole cell preparations.
[3H]-RX821002 does not enter whole cells, and thereby it labels
plasma membrane receptors from the extracellular side only
(Jahnsen and Uhlén, 2012). Whole HEK293 cells (150 μl suspen-
sion) pre-incubated with competitors (19xKi) in a microtiter-plate
can be centrifuged at 3000 rpm (1110 g) for three min, attaching
the cells to the bottom surface. Then, turning the microplate up-
side-down and centrifuging at 600 rpm (44 g) for 10 s removes
essentially all medium into the attached waste container. Im-
mediately after the centrifugation process, 300 μl of [3H]-
RX821002 was quickly and rather forcefully added to the cells. This
action resulted in the re-suspension of most of the cells in one
step. Assuming pre-bound competitor does not start to dissociate
from the receptors until the addition of the diluting buffer, in-
cluding the radioligand, the on-reaction for [3H]-RX821002 and
the off-reaction for the pre-bound competitor start
simultaneously.
3.2. Experimental koff and kon values for [
3H]-RX821002 at the α2A-,
α2C-, and two chimeric α2-adrenoceptors
In Fig. 1(A) is shown the on-rate curves for [3H]-RX821002,
obtained at whole cells expressing α2A, α2C, and two chimeric α2-
adrenoceptors. The curves represent the binding of [3H]-RX821002
at various time points after adding the radioligand. The association
t1/2 values at the various receptors were in the range 0.5–3 min
Fig. 1(B) shows the off-rate curves for [3H]-RX821002 from its
equilibrium binding state. The procedure was to add an excess of
atipamezole after a 60 min of pre-incubation with [3H]-RX821002,
and then ﬁltering at various time points. The dissociation t1/2 va-
lues at different receptors were in the range 3–6 min. Among the
α2A-, α2C-and chimeric α2-adrenoceptors, the on-rate constant
(kon) of [3H]-RX821002 was highest at the α2C- and AppC-re-
ceptors, while the off-rate constant (koff) was highest at the α2C-
and CppA-receptors (Table 1). The calculated Kd values, i.e. the koff/
kon ratios, were 2.06 nM at the α2A-, 1.26 nM at the α2C-adreno-
ceptors, 0.38 nM at the AppC receptor and 4.90 nM at the CppA
receptor. The order of these values corresponds to thecorresponding Kd values determined by equilibrium binding
(Jahnsen and Uhlén, 2013). The kinetically determined Kd values
are slightly higher than the Kd values determined at equilibrium,
an effect likely induced by the high concentration of blocking
competitor added in the off-rate experiments (see Vauquelin and
van Liefde, 2012).
3.3. Experimental koff values and calculated kon values for unlabeled
ligands at the α2A-, α2C-, and two chimeric α2-adrenoceptors
Fig. 1(C)-(F) show the on-rate curves for [3H]-RX821002 after
pre-incubation with competitors. Displaying the curves in a semi-
logarithmic plot, the curves are shifted to the right as compared to
the antagonist-free control time-curve, though not in parallel since
the blocking effect of the pre-incubated ligands is largest at early
time points. The binding curves, which are inﬂuenced by the off-
rates of the competitors, look quite similar among the α2A- and
CppA- receptors, and so are the binding curves among the α2C-
and AppC- receptors. This implies the C-terminal half of these
receptors has the largest subtype-selective inﬂuence on the off-
rate of the ligands, conﬁrming that the C-terminal half of these
receptors is the main determinant for the receptor’s drug se-
lectivity (Jahnsen and Uhlén, 2013).
Table 2 shows the experimentally obtained koff values for the
tested compounds. The lowest off-rate was for MK912 at the α2C-
adrenoceptor (koff¼0.00477 min1), indicating a half-life of bound
MK912 of 145 min, at room temperature. Despite its high afﬁnity,
the ligand atipamezole showed a koff value of 1.156 at the α2C-
adrenoceptor, indicating a half-life of bound atipamezole of 36 s.
For ligands having half-lives shorter than 30 s accurate koff values
could not be obtained using our assay. Therefore, for chlorpro-
mazine no accurate koff values were obtained, and for BRL44408
the only accurate koff values obtained was the koff value at the α2A-
adrenoceptor.
Dividing the koff values from Table 2 with the Ki values of the
ligands yields the calculated kon values (kon¼ koff/Ki). The Ki values
of RS79948–197 and yohimbine were obtained in the present
study, while the Ki-values of all the other tested compounds had
already been determined in our previous study (Jahnsen and Uh-
lén, 2013). The here obtained Ki values of RS79948–197 at the four
tested receptors were 0.24570.138 at the α2A, 0.22170.121 at the
α2C, 0.23670.108 at the AppC and 0.19870.025 at the CppA re-
ceptors. The Ki values for yohimbine were 1.8870.10 at the α2A,
1.0670.47 at the α2C, 1.7170.79 at the AppC and 1.9970.84 at
the CppA receptors. The number of experiments were n¼3 at the
α2A- and α2C-adrenoceptors, and n¼4 at the AppC and CppA
receptors.
The calculated kon constants are shown in Table 3. As can be
seen in Table 3, the ligand with the lowest calculated kon value was
yohimbine at the α2A-adrenoceptor (kon¼0.0152 nM1 min1).
The ligand with the highest calculated kon value was atipamezole
at the AppC receptor (kon¼1.671 nM1 min1).
Table 4 shows the α2C/α2A selectivity ratios of six ligands, re-
garding koff constants, kon constants, and afﬁnities. The drugs with
lowest koff ratio between α2C/α2A were spiroxatrine and MK912.
This contributes to their α2C-selectivity. The drug with the highest
kon ratio between α2C/α2A was spiroxatrine. The high on-rate and
slow off-rate for spiroxatrine at the α2C-adrenoceptor makes
spiroxatrine markedly α2C-selective.
The results show that the α2C- over α2A-adrenoceptor se-
lectivity of MK912 depends mainly on a very low off-rate for
MK912 at the α2C-adrenoceptor. On the other hand, the α2C- over
α2A-selectivity of spiroxatrine depends both on its high on-rate as
well as on its low off-rate at the α2C-adrenoceptor. Atipamezole
showed very high off-rate at the α2A- and α2C-adrenoceptors, but
still shows high afﬁnity thanks to its concomitant very high on-
Table 2.
Experimental koff dissociation rate constants for pre-incubated ligands, determined at native α2A- and α2C-adrenoceptors and at two chimeric receptors. Shown are the koff7
StdP values (unit min1), and number of experiments. The koff values in Table 2 are also presented graphically in Fig. 2(A).
Ligand α2A α2C AppC CppA
MK912 0.060670.0167 (10) 0.004870.0034 (12) 0.006670.0026 (9) 0.044270.0072 (8)
RS79948–197 0.013570.0022 (6) 0.028170.0058 (6) 0.020270.0032 (3) 0.022170.0070 (3)
spiroxatrine 0.64270.455 (9) 0.046670.0129 (12) 0.043070.0179 (10) 0.40370.354 (8)
yohimbine 0.028570.0054 (6) 0.095570.0512 (6) 0.12670.021 (3) 0.15370.116 (3)
RX821002 0.073470.0145 (9) 0.21670.134 (12) 0.082370.0215 (10) 0.14170.034 (9)
atipamezole 0.86570.464 (8) 1.15670.484 (9) 0.66570.318 (9) 0.93970.587 (6)
clozapine 41.386 (6) 1.75670.602 (6) 1.49871.002 (5) 1.62970.330 (3)
BRL44408 1.30870.393 (7) 41.386 (8) 41.386 (8) 41.386 (8)
chlorpromazine 41.386 (8) 41.386 (4) 41.386 (4) 41.386 (4)
Table 3.
Calculated kon association rate constants (nM1 min1) for the pre-incubated li-
gands at native α2A- and α2C-adrenoceptors and at two chimeric receptors. The
formula used is kon¼koff/Ki. The koff values were taken from Table 2. The Ki values
were taken from Jahnsen and Uhlen, 2013, except for RS79948–197 and yohimbine
where the Ki values were obtained in the present study. The calculated kon values in
Table 3 are also presented graphically in Fig. 2(B).
Ligand α2A α2C AppC CppA
MK912 0.0798 0.0467 0.106 0.0609
RS79948–197 0.0549 0.127 0.0854 0.111
spiroxatrine 0.0268 0.112 0.121 0.0320
yohimbine 0.0152 0.0901 0.0736 0.0771
RX821002 0.164 0.440 0.343 0.161
atipamezole 0.971 1.297 1.671 0.763
clozapine – 1.112 0.462 0.087
BRL44408 0.217 – – –
chlorpromazine – – – –
Table 4.
Ratio of α2C- over α2A-selectivity for 7 ligands, regarding dissociation rates, asso-
ciation rates, and afﬁnities. In the second column is shown the calculated α2C/α2A
koff values ratio. In the third column is shown the calculated α2C/α2A kon values
ratio. These ratios were calculated from data presented in the previous tables. In
the fourth column are shown the α2C- over α2A-selectivity of the ligands, calculated
from the kon value ratios in column 3 divided with the koff value ratios in column 2.
The same α2C- over α2A-selectivity value is extractable from the Ki values, since the
kon values were derived by calculation from the ligand’s koff and Ki values.
Ligand Ratio of dissocia-
tion rates (koff α2C/
koff α2A)
Ratio of associa-





MK912 0.079 0.59 7.44
RS79948–197 2.09 2.31 1.11
spiroxatrine 0.073 4.18 57.6
yohimbine 3.35 5.93 1.77
RX821002 2.94 2.68 0.91
[3H]-RX821002 2.11 2.42 1.14
atipamezole 1.34 1.34 1.00
Fig. 2. A-B. Staple diagram of the koff and kon constants for unlabeled competitors.
Section A shows experimental koff constants for [3H]-RX8321002 and 8 unlabeled
competitors, at the α2A, α2C, AppC, and CppA receptors. The receptors are indicated
below the x-axis by the letters A, C, AC, and CA. Section B shows the experimental
kon constant for [3H]-RX8321002 and the calculated kon constants for the 8 un-
labeled competitors. Cut-offs were set at koff¼1.386 min1 and
kon¼1.386 nM1 min1. At higher koff values half of the dissociation occurs in less
than 30 s, and therefore determination of off-rate constants above this value is less
accurate.
S. Uhlén et al. / European Journal of Pharmacology 788 (2016) 113–121118rate (see Fig. 2(A)-(B)).
3.4. Afﬁnity range for applicability of the experimental method
The dissociation of MK912, RS79948–197, spiroxatrine, yo-
himbine, and RX821002 had t1/2 values above one min at the re-
ceptors. These ligands produced a clear delay of [3H]-RX821002
binding. Atipamezole, BRL44408, and chlorpromazine had t1/2
values near or below one min at the receptors, and the calculated
koff values for these drugs are therefore less adequate. Never-
theless, it is clear that chlorpromazine dissociates quickly from all
the tested receptors. As a rule of thumb, the methodology enabled
clear detection of the off-rate constant for unlabeled ligands with
Ki values in the range 200 pM– 10 nM. The drug with lowest af-
ﬁnity where koff still was detectable was spiroxatrine at α2A, wherethe Ki value was 24 nM, and the koff value 0.64 min1 (Table 3).
This is a fairly low koff value, and low off-rate, for such a low-af-
ﬁnity drug, so the low afﬁnity seems to be caused by a corre-
sponding low kon value. The drug with highest afﬁnity that still
dissociated completely within 72 min was RX821002 at AppC,
where the Ki value was 0.24 nM and the koff value 0.082 min1
(Table 3). Since, RX821002 had rather high on- and off-rates, the
half-life of bound RX821002 was fairly short despite its high afﬁ-
nity, namely about 8 min (t1/2¼ ln2/koff).4. Discussion
4.1. A radioligand binding experimental design for determining the
Fig. 3. Model of ligand-receptor interactions. The lower part of the ﬁgures re-
presents the proper binding site with ligand bound to the receptor. Here the afﬁnity
of a ligand is inﬂuenced by the number of contact points and by the strength of the
bonds. The upper part of the ﬁgures represents the translocation pathway for a
ligand to and from the binding site of the receptor, with arrows indicating fast or
slow movements. Together, the bonds and the translocation processes deﬁne the
kon and koff values, and thereby the afﬁnity of a ligand for a receptor.
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The major aim of the present study was to develop a simple
radioligand binding experimental design for determining the ki-
netic off-rate constants for unlabeled drugs. Previous radioligand
binding studies, including in-depth mathematical analysis, have
been performed, characterizing the kinetics of competitive binding
at β-adrenoceptors (Motulsky and Mahan, 1984), muscarinic re-
ceptors (Schreiber et al., 1985; Dowling and Charlton, 2006), D2
dopamine and CB1 cannabinoid receptors (Packeu et al., 2010), and
adenosine A1 receptors (Sykes et al., 2010; Guo et al., 2013; Xia
et al., 2016). Most of the methods used in these studies have
limitations, either due to high complexity or due to narrow ap-
plicability. In an all-at-once assay, several factors ([C], [CR], [R], [L]
and [LR]) are varying simultaneously, and four different kinetic
constants are involved (k1, k2, k3, k4) (see Motulsky and Mahan,
1984). Using a two-step method, as in the present study, the only
unknown kinetic constant in the ﬁnal on-rate curve for the radi-
oligand is the koff constant of the unlabeled competitor (k4). Thus,
the on-rate constant for the radioligand (k1) is set constant with
the value obtained from the control curve. The off-rate constant
for the radioligand (k2) is known from previous experiments (Ta-
ble 1). The on-rate constant for the competitor (k3) becomes re-
dundant by the efﬁcient washing-out of the competitor.
The results conﬁrm that the experimental concept works, the
wet-lab methodology essentially consisting of pre-incubation of
receptors at whole cells with competitor, then quick washout by
upside-down centrifugation, followed by performing the on-re-
action for the radioligand. In the analysis, the koff constant of the
unlabeled competitor was calculated by fairly simple curve ﬁtting
mathematics (Eq. (2)), derived from the differential equation (Eq.
(1)) of Malany et al. (2009). Our results show that spiroxatrine
associates slowly and dissociates rapidly at the α2A- and the CppA-
receptors. Conversely, at the α2C- and AppC-adrenoceptors, spir-
oxatrine associates rapidly and dissociates slowly. This pattern
constitutes the α2C- and AppC-selectivity of spiroxatrine. Regard-
ing MK912, the off-kinetics experiments showed that MK912 dis-
sociated very slowly from α2C and AppC. In PET studies it has been
shown that [11C]MK-912 washed out problematically slow from
the brain (Shiue et al., 1998). A contributing reason for this slow
washout might be the low off-rate of MK912 at α2C-adrenoceptors,
as shown in the present study.
4.2. Kinetic parameters of ligand-receptor interactions
There are two established methodologies for studying the ki-
netic component of ligand-receptor interactions, namely radi-
oligand binding and surface plasmon resonance, while several
ﬂuorescence-based methods were classiﬁed as in development
[Hoffmann et al., 2015]. However, it is not until just recently that
surface plasmon resonance technique (Biacore) has been used for
determining the kinetic constants for small molecules interacting
with G protein-coupled receptors (Rich et al., 2011). This technique
still is laborious in the preparation of receptor-coated sensor chips
and it is more difﬁcult to analyze the binding kinetics for small
molecules than for larger molecules. A different but technically
advanced method is currently developed, namely a single mole-
cule nanoscopic method for tip-attached peptides, enabling de-
tection of the contact force between the ligand and receptor, i.e.
measuring the required off-kinetic energy (Alsteens et al., 2015).
To large extent, the off-kinetic energy determines the residence
time for a ligand at a receptor. Copeland and coworkers deﬁned
the term residence time to refer to the temporal duration of the
binary receptor-ligand complex, and stated that the residence time
is affected by the dissociation rate (see Copeland, 2016). According
to Copeland et al. (2006) the residence time (τ) is deﬁned by τ¼1/koff, making residence time proportionally 1.443 times longer than
dissociation half-life deﬁned by t1/2¼ ln2/koff. Thus, in mass action
kinetics, residence time and dissociation half-life are inter-
changeable. These two time-constants do not fully deﬁne ligand
afﬁnity or receptor occupancy, which according to the law of mass
action are dependent on both the on- and off-rates. However, at
the individual receptor level, the residence time of a ligand might
inﬂuence its biological effect, so the quantitative assessment of
this parameter has a role in the overall evaluation of receptor-li-
gand interactions in pharmacology (Tummino and Copeland,
2008; Guo et al., 2014; Hothersall et al., 2016; Vauquelin, 2015).
Intuitively, residence time can be mistaken for the temporal pre-
sence of the ligand-receptor complex, i.e. receptor occupancy 
Bmax  time ((mol/liter)xmin), which is visualized as an area
under the curve. However, residence time in the simplest model
(Hothersall et al., 2016) is just a time point (min) at the dissocia-
tion curve. In binding kinetics experiments, the temporal presence
of the ligand-receptor complex becomes larger with faster on-rate
or slower off-rate, while residence time only is inﬂuenced by the
off-rate. In our experiments, the observed koff values reﬂect de-
tachment and dissociation from the receptor, i.e. the freeing of the
receptor from pre-bound competitor. This rate is somewhat
modiﬁed by immediate re-binding of the ligand to the original
receptor, i.e. by a local un-binding - re-binding process (see Vau-
quelin, 2016 in press). Thus, our observed koff value represents
dissociation of the ligand all the way out of the receptor (Fig. 3),
which may resemble a true situation at individual receptors.
4.3. The chimeric AppC and CppA receptors
The chimeras were designed in order to evaluate whether the
ﬁrst transmembrane helix of the α2A-adrenoceptor is indirectly
interacting with the second extracellular loop of the receptor, hy-
pothetically inducing slow on-rate (or fast off-rate) for bulky drugs
like chlorpromazine, rauwolscine and spiroxatrine at the α2A-sub-
type, and thereby induce α2C- over α2A- selectivity (Laurila et al.,
2011). Our results could not conﬁrm any hypothetical interaction
between TM1 and extracellular loop 2 in the α2A-adrenoceptor, such
that bulky drugs would associate slowly and/or dissociate rapidly at
the α2A- but not at all of the α2C-, AppC and CppA-receptors. That
complete pattern was in fact not observed for any of the four suc-
cessfully tested bulky ligands MK912, RS79948–197, spiroxatrine or
yohimbine. For example, the speciﬁcally slow on-rate of spiroxa-
trine was shared among the α2A- and the CppA-receptors, even
though the CppA-receptor has its ﬁrst transmembrane helix from
S. Uhlén et al. / European Journal of Pharmacology 788 (2016) 113–121120the α2C-adrenoceptor. However, a general observation was that
most of the tested ligands had slower on-rates at the α2A- as
compared to at the α2C-adrenoceptor (Fig. 2(B)).
4.4. Off-rate detection range between too fast and too slow off-rates
for the pre-incubated ligands
Among the herein tested drugs the detection range corre-
sponded to drugs with Ki values in the range 0.210 nM. Drugs
with Ki values above 10 nM tended to have too high off-rate for the
koff constant to be detectable. The fact that low afﬁnity drugs
usually have high off-rates is obvious from the formula Ki¼koff/
kon. However, for analysis of drug binding to receptors there are
plenty of substances with Ki values in the range 0.210 nM, and
among them some may show unexpected on- or off-rates at var-
ious receptors.
4.5. Kinetic ligand-receptor interactions
In the present study we show that the on-reaction rate may
vary substantially among different drugs as well as for any drug at
two different receptors (Table 2). The results implies that the on-
rate for a ligand is dependent on diffusion, positioning at the re-
ceptor, and attachment to the binding site, while the off-rate is
dependent on detachment and diffusion away from the binding
site. The physical bond forces at the binding site constitute the
main factor in determining the dissociation half-life and afﬁnity of
a ligand for the receptor, but the on- and off-movements of the
ligand may also play a role for its afﬁnity. Thus, in a recent mo-
lecular dynamics simulation and experimental study it was de-
monstrated that even receptor features with little contribution to
afﬁnity may prove critical to the dissociation process (Guo et al.,
2016). The fact that some drugs, like spiroxatrine, have a higher
kon constant at the α2C- than at the α2A-adrenoceptor seems to
indicate that the α2A- and α2C-adrenoceptors interact differentially
with spiroxatrine at the entrance process for the drug. RS79948
and yohimbine moved slowly in and out of the binding site at all
tested receptors, while RX821002 and atipamezole moved fast in
and out. Notably, MK912 dissociates extremely slowly from the
α2C-adrenoceptor subtype. Finally, at the α2C-adrenoceptor sub-
type, spiroxatrine enters the binding site fast, but dissociates
slowly, explaining its α2C-selectivity. In Fig. 3 we present a model
where the movements of the ligand are separated from the phy-
sical bonds between ligand and binding site. The model is meant
to illustrate a theoretical separation between on one hand the
movements of the ligand into and out of the binding site, and on
the other hand the physical binding force keeping the ligand at-
tached at the binding site. The model gives an idea about what is
deﬁning the afﬁnity of a reversible drug for the receptor, and may
help theorists reﬁne in silico receptor models. For example, the
afﬁnity of a prospective ligand could be optimized, by creating a
new molecular structure, having a higher on-rate.Authorship contributions
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